MaxCyte to Buy Akron Bio, Expects Deal to Nearly Double Revenue Base
MXCT sits 91% above its 52-week low of $0.643.
Summary
MaxCyte has agreed to acquire Akron Bio from Arcline Investment Management for $151.8 million, adding cell therapy manufacturing capabilities to its portfolio, and expects the deal to nearly double its revenue base. Akron Bio is expected to generate about $28 million in 2026 revenue. MaxCyte will pay $105 million in cash and 20.6 million shares at closing. That is a big claim for a company with a $134M market cap whose Q2 2026 revenue was $7.3M, down 15% year-over-year, before Q3 core revenue rebounded to about $8.1M, up 26%, with raised full-year guidance; Q3 revenue was $10.2M and the quarterly loss per share was 5c, with Q3 adjusted EBITDA of -5.1 million versus an IBES estimate of -7.99 million. The strategic logic is consolidation across cell therapy manufacturing. Watch whether the combined revenue run-rate matches the 'nearly double' framing.
At the time of this announcement, MXCT was trading at $1.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $134.2M. The 52-week trading range was $0.64 to $1.81. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.